Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated influenza vaccine
- Development stage
- Approved
- Lead developer
- CSL
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent inactivated influenza vaccine (TIV or IIV3) is a synthetic vaccine composed of three inactivated (killed) influenza viruses—two different type A strains (H1N1 and H3N2 subtypes) and one type B strain (Victoria lineage). It is administered by injection and works by stimulating the immune system to produce antibodies against these specific viral antigens. The primary indication is the prevention of seasonal influenza infection. The mechanism of action involves exposure to viral hemagglutinin proteins from the selected strains; this induces an adaptive immune response that provides protection if exposed to circulating viruses matching those included in the vaccine[1][3][4]. TIV does not cause flu illness as it contains only killed virus or purified viral proteins[4]. It is recommended for annual use in all individuals aged 6 months and older[1].
- Brand names
- FluadFlucelvax TrivalentAfluriaEnziraFluvaxNilgripAgrippalBegripalFluazurSandovacAgrifluChiroflu
- Other names
- trivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on trivalent inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated influenza vaccine.